BioVectra Receives the 2025 CDMO Leadership Award for Biologics

BioVectra Receives the 2025 CDMO Leadership Award for Biologics

Biovecrectra, part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics and complex chemistry, proudly announced that it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the biologics category. The award recognizes Biovectra's performance in key areas such as quality, reliability and technical capability.

“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and provide such an important tool for drug sponsors to select their best partner to bring life-saving therapies to market.”said Louis Garguilo, Editor-in-Chief at Outsourced Pharma."The new categories and improved scoring methodology submitted in this year's review bring an improved experience for drug sponsors using the resource, as well as an ever-coveted award for CDMOs. The unveiling of the honoree during our celebration in March will be an exciting new addition to the celebrations."

For the past fourteen years, the CDMO Leadership Awards have recognized world-class contract development and manufacturing organizations based on industry research and sponsor feedback, providing drug developers insight into highly rated outsourcing partners.

This award is a testament to Biovecrectra / Agilent's deep commitment to a customer-first approach rooted in scientific excellence and manufacturing solutions. “

Brian Carothers, vice president and general manager, Advanced Manufacturing Partnerships Division, Agilent Technologies

"We are honored to have our team's commitment to advancing biologics and setting new standards recognized by industry leaders. From process development to commercial concentration production, we remain focused on delivering high-quality biomanufacturing solutions that help accelerate our customers' path to market."

BioVectra will celebrate this achievement alongside other honorees at the CDMO Leadership Awards ceremony in New York City on March 19, 2025.

BioVectra supports customers in the biologics supply chain with advanced capabilities and expertise in microbial fermentation, protein purification and single-use technologies. Its GMP certified facilities provide clinical to commercial scale manufacturing, including aseptic filler capabilities for injectable therapies. The Company's investment in advanced bioproduction technologies and flexible manufacturing infrastructures enable drug sponsors to optimize development timelines while maintaining regulatory compliance.

Sources: